Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide
NCT03298802 · The University of Texas Medical Branch, Galveston · PHASE3 · terminated · last registry update 2026-07-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Futility of the study” | – | Registry record, The University of Texas Medical Branch, Galveston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-05Results posted on the registry: Vanderbilt University Medical Center, Empiric Therapy: Drug + Selective Therapy: Drug (NCT05365477)
- 2026-09-15Results posted on the registry: Brigham and Women's Hospital, Eplerenone + Chlorthalidone with potassium chloride (NCT04519164)
- 2026-05-08Also stopped (terminated): University of Alberta, Furosemide + Chlorthalidone (NCT05915286)
- 2026-03-13Phase 3 first posted: Hospital de Clinicas de Porto Alegre, Furosemide 40 Milligrams. + Furosemide 40 Milligrams. (NCT07469722)
- 2026-01-13Also stopped (terminated): University of California, San Francisco, Anti-hypertensive agent: amlodipine + Anti-hypertensive agent: Chlorthalidone (NCT05370599)
- 2025-12-08Also stopped (withdrawn): EMS, Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg + Olmesartan medoxomil 20mg + Chlortalidone 25mg (NCT02493322)
- 2025-12-08Also stopped (withdrawn): EMS, Olmesartan medoxomil 40mg + chlorthalidone 12,5mg + Olmesartan medoxomil 40mg + chlorthalidone 25mg (NCT02483936)
- 2025-11-18Phase 3 first posted: Yan Li, a drug against SLC12A3 (NCT07232966)
- 2025-08-12Phase 3 first posted: Kyungdong Pharmaceutical Co., Ltd., KDF1901-R0 + KDF1901-L (NCT07116863)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
- 2025-07-29Results posted on the registry: Prevencion, Hydrochlorothiazide + Amlodipine (NCT02373163)
- 2025-07-22Results posted on the registry: University of Alabama at Birmingham, Perindopril + Losartan (NCT03295734)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision